Human Progesterone A-Form as a Target for New Drug Discovery in Human Breast Cancer
Annual summary repy. 1 Jul 1998-30 Jun 2002
DUKE UNIV MEDICAL CENTER DURHAM NC
Pagination or Media Count:
The role of the estrogen receptor ER in breast cancer has been suggested both by its ability to stimulate cell proliferation as well as the observation that ER is expressed ir 60 of primary breast tumor biopsies but only in 6 of normal breast tissue. Drugs which interfere with ER activity such as the antiestrogen Tamoxifen have been only partially successful in the treatment of breast cancers emphasizing the need for new targets as well as new pharmacological agents against these targets. The observation that antiprogestins such as RU486 could function as antiestrogens suggested that the progesterone receptor PR could be a potential target in the treatment of breast cancers. The goal of this project was to elucidate the mechanism of hPR-A transdominant repression by characterizing potential hPR-A-interacting partners which are necessary for ER transcriptional activation. We anticipate that new pharmacological agents against these targets could be used to treat breast cancers which currently escape endocrine intervention.
- Medicine and Medical Research